Marijn C Verwijs
Overview
Explore the profile of Marijn C Verwijs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verwijs M, Agaba S, Umulisa M, van de Wijgert J
Sex Transm Infect
. 2021 Jan;
98(1):58-61.
PMID: 33514681
Objectives: To establish temporal links between vaginal microbiota (VMB) data and incident clinical events, frequent longitudinal vaginal sampling is required. Self-collection of swabs at the participant's home may be useful...
2.
van de Wijgert J, Verwijs M
N Engl J Med
. 2020 Aug;
383(8):790-791.
PMID: 32813958
No abstract available.
3.
Verwijs M, Agaba S, Umulisa M, Uwineza M, Nivoliez A, Lievens E, et al.
BMJ Open
. 2020 May;
10(5):e031819.
PMID: 32434932
Objectives: To evaluate adherence and acceptability of intermittent vaginal probiotic or antibiotic use to prevent bacterial vaginosis (BV) recurrence. Design: Repeated adherence and acceptability assessments using mixed methods within a...
4.
van de Wijgert J, Verwijs M, Gill A, Borgdorff H, van der Veer C, Mayaud P
Front Cell Infect Microbiol
. 2020 May;
10:129.
PMID: 32351902
Sequencing studies have shown that optimal vaginal microbiota (VMB) are lactobacilli-dominated and that anaerobes associated with bacterial vaginosis (BV-anaerobes) are commonly present. However, they overlooked a less prevalent but more...
5.
van de Wijgert J, Verwijs M, Agaba S, Bronowski C, Mwambarangwe L, Uwineza M, et al.
Sci Rep
. 2020 Mar;
10(1):3884.
PMID: 32127550
Bacterial vaginosis (BV) is associated with HIV acquisition and adverse pregnancy outcomes. Recurrence after metronidazole treatment is high. HIV-negative, non-pregnant Rwandan BV patients were randomized to four groups (n =...
6.
7.
van de Wijgert J, Gill A, Chikandiwa A, Verwijs M, Kelly H, Omar T, et al.
AIDS
. 2019 Oct;
34(1):115-125.
PMID: 31567164
Objectives: To assess the associations between microbiological markers of vaginal dysbiosis and incident/cleared/type-swap/persistent high-risk human papillomavirus (hrHPV) infection; and incident/cured/cleared/persistent high-grade cervical intraepithelial neoplasia (CIN2+) while controlling for persistent hrHPV...
8.
Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure
Verwijs M, Agaba S, Darby A, van de Wijgert J
Am J Obstet Gynecol
. 2019 Aug;
222(2):157.e1-157.e13.
PMID: 31404542
Background: Metronidazole is the first-line treatment for bacterial vaginosis, but cure rates are suboptimal and recurrence rates high. Objectives: To evaluate the impact of a standard course of oral metronidazole...
9.
Verwijs M, Agaba S, Sumanyi J, Umulisa M, Mwambarangwe L, Musengamana V, et al.
Lancet Infect Dis
. 2019 Apr;
19(6):658-669.
PMID: 31031172
Background: Sexually transmitted and urogenital infections are typically managed by WHO-recommended syndromic algorithms in resource-poor countries, and presumptively in Europe. However, algorithms for vaginal discharge and lower abdominal pain perform...
10.
Borgdorff H, Verwijs M, Wit F, Tsivtsivadze E, Ndayisaba G, Verhelst R, et al.
Sex Transm Dis
. 2015 Feb;
42(3):143-52.
PMID: 25668647
Background: The observed association between Depo-Provera injectable use and increased HIV acquisition may be caused by hormone-induced increased susceptibility to other sexually transmitted infections (STIs) or changes in the cervicovaginal...